Chinese Physicians' Knowledge, Perspectives, and Clinical Application of Vonoprazan for Treating Helicobacter Pylori Infection and Gastroesophageal Reflux Disease: A Nationwide Cross-Sectional Analysis - Takeaways - MDSpire

Chinese Physicians' Knowledge, Perspectives, and Clinical Application of Vonoprazan for Treating Helicobacter Pylori Infection and Gastroesophageal Reflux Disease: A Nationwide Cross-Sectional Analysis

  • By

  • Hui Xu

  • Hao Zhao

  • Heqing Tao

  • Ligang Liu

  • November 11, 2025

  • 0 min

Share

  • 1

    Helicobacter pylori infection and gastroesophageal reflux disease are prevalent public health issues in China, affecting 42.8% and 10.6% of the population, respectively.

  • 2

    Current guidelines recommend bismuth quadruple therapy and high-dose dual therapy for H. pylori, while PPIs are commonly used for GERD management.

  • 3

    Vonoprazan, a potassium-competitive acid blocker, offers potential advantages over PPIs, including rapid activation and durable acid suppression.

  • 4

    The study aimed to assess Chinese physicians' awareness, clinical use, and perceptions of vonoprazan for treating H. pylori and GERD.

  • 5

    A web-based survey was conducted among licensed physicians to evaluate their knowledge and attitudes towards vonoprazan's efficacy and safety.

Original Source(s)

Chinese Physicians' Knowledge, Perspectives, and Clinical Application of Vonoprazan for Treating Helicobacter Pylori Infection and Gastroesophageal Reflux Disease: A Nationwide Cross-Sectional Analysis

  • by Hui Xu, Hao Zhao, Heqing Tao, Ligang Liu

  • November 11, 2025

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Clinical significance of hiatus hernia on Barrett’s oesophagus: a scoping review

Postoperative Swallowing Difficulties and Immediate Outcomes After Laparoscopic Floppy Nissen Fundoplication with V-flap Suturing